News and Press Releases
Neogap secures SEK 87 million to advance clinical development of its personalised immunotherapy
11 February 2026 -- Solna, Sweden -- Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has raised SEK 87 million in a financing round led...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2026
Stiftelsen Cancercentrum Karolinska (CCK) Visionsgatan 56 171 64 Solna, Sweden
Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...
Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025
Campus Biotech Innovation Park Avenue Sécheron 15
1202 Genève
Switzerland
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
7 April 2025 -- California, US -- ImmunityBio, Inc, a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at...
Category: Drug Discovery, Other, Pharmaceutical
Posted: April 7, 2025
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: November 25, 2024
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time Two participants met criteria for functional cure Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. 15 November 2024 -- Oxford,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 15, 2024
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024
Barinthus Bio Names Experienced Physician, Leon Hooftman MD, as Chief Medical Officer
Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, haematology, oncology and infectious diseases 1 May 2024 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical...
Category: BioManufacturing, Drug Discovery
Posted: May 1, 2024
New partnership aims to advance vaccine against MERS coronavirus
CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses...
Category: Clinical Trials
Posted: January 2, 2024
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level...
Category: Drug Discovery
Posted: November 27, 2023
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data 6 November 2023 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel...
Category: Drug Discovery
Posted: November 27, 2023
